PT-141 (Bremelanotide) is a synthetic peptide originally derived from Melanotan II. Unlike other sexual health therapies that act on the
vascular system, PT-141 works directly on the nervous system to enhance sexual desire and arousal. It has been studied in both men and
women for treatment of sexual dysfunction.
Key Benefits
• Sexual Health Support: Enhances libido and sexual arousal.
• Unique Mechanism: Targets melanocortin receptors in the brain, not the vascular system.
• Broad Applications: Studied in both male erectile dysfunction and female sexual interest/arousal disorder.
• Rapid Onset: Effects reported within hours of administration.
Clinical Findings
• FDA-approved under the name Vyleesi for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
• Studies show improvement in erectile function in men.
• Demonstrated efficacy in individuals unresponsive to PDE5 inhibitors (e.g., sildenafil).
Safety & Tolerability
• Common side effects: flushing, nausea, headache, injection site reactions.
• Some individuals may experience transient increases in blood pressure.
• Contraindicated in uncontrolled hypertension or cardiovascular disease.
Dosing
• Typical Protocol (FDA-approved use): 1.75 mg subcutaneous injection ~45 minutes before anticipated sexual activity.
• Frequency: Not to exceed one dose per 24 hours or 8 doses per month.
• Research protocols may vary depending on study design.
For research and informational purposes only – not for medical use.




Reviews
There are no reviews yet.